Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas

Inclusion Criteria: * Participants must have histologically confirmed intracranial meningioma, grade II-III,that has recurred or progressed at previous treatment. * Participants must be willing and able to undergo regular MRI scans of the brain. * Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension as ≥10 mm with MRI, performed within 30 days prior to study registration. * Patients must have received prior surgical resection and radiation therapy for the progressive meningioma. * Patients must have received less than three prior chemotherapy regimens for progressive meningioma. * Patients must have available an archival paraffin tumor block sufficient to generate at least 20 unstained slides; or, if a paraffin tumor block is unavailable, at least 20 unstained slides. * Age ≥ 18 years at the time of study enrollment. * ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A) with no deterioration over the previous 2 weeks. * Life expectancy of greater than three months * Within 14 days of study registration, participants must have normal organ and marrow function as defined below: * leukocytes ≥3,000/mcL * absolute neutrophil count ≥1,500/mcL * hemoglobin ≥90 g/L * platelets ≥100,000/mcL * total bilirubin ≤1.5 x institutional upper limit of normal * AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal * Serum creatinine ≤1.5 x institutional upper limit of normal concurr…